Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ADORA2A | P29274 | 7/20 | 0.58 |
| ▸ | PDE4A | P27815 | 4/20 | 0.58 |
| ▸ | PDE4B | Q07343 | 4/20 | 0.58 |
| ▸ | PDE4C | Q08493 | 4/20 | 0.58 |
| ▸ | PDE4D | Q08499 | 4/20 | 0.58 |
| ▸ | ADORA2B | P29275 | 5/20 | 0.55 |
| ▸ | ADORA3 | P0DMS8 | 2/20 | 0.55 |
| ▸ | ADORA1 | P30542 | 2/20 | 0.55 |
| ▸ | HPGD | P15428 | 1/20 | 0.55 |
| ▸ | BLM | P54132 | 1/20 | 0.55 |
| ▸ | PDE3A | Q14432 | 1/20 | 0.55 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.55 |
| ▸ | PNP | P00491 | 2/20 | 0.53 |
| ▸ | GDA | Q9Y2T3 | 2/20 | 0.43 |
| ▸ | ACHE | P22303 | 1/20 | 0.43 |
| ▸ | DAO | P14920 | 1/20 | 0.42 |
| ▸ | MPO | P05164 | 2/20 | 0.41 |
| ▸ | TPO | P07202 | 2/20 | 0.41 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.41 |
| ▸ | ATAD2 | Q6PL18 | 1/20 | 0.40 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| 3-Methylxanthine SCHEMBL237146 | 0.81 | ADORA2A (0.64) | ADORA2APDE4APDE4BPDE4CPDE4D | |
| 3-Methylxanthine SCHEMBL4020124 | 0.80 | ADORA2A (0.62) | ADORA2APDE4APDE4BPDE4CPDE4D | |
| 3-Methylxanthine SCHEMBL9317914 | 0.80 | ADORA2A (0.62) | ADORA2APDE4APDE4BPDE4CPDE4D | |
| SCHEMBL18112639 | 0.78 | ADORA2A (0.58) | ADORA2APDE4APDE4BPDE4CPDE4D | |
| SCHEMBL28142117 | 0.78 | ADORA2A (0.58) | ADORA2APDE4APDE4BPDE4CPDE4D | |
| SCHEMBL5513199 | 0.78 | ADORA2A (0.58) | ADORA2APDE4APDE4BPDE4CPDE4D | |
| SCHEMBL28337267 | 0.78 | ADORA2A (0.58) | ADORA2APDE4APDE4BPDE4CPDE4D | |
| SCHEMBL3699117 | 0.75 | PDE4A (0.73) | ADORA2APDE4APDE4BPDE4CPDE4D | |
| SCHEMBL5515323 | 0.74 | ADORA2A (0.71) | ADORA2APDE4APDE4BPDE4CPDE4D | |
| SCHEMBL20653044 | 0.74 | ADORA2A (0.58) | ADORA2APDE4APDE4BPDE4CPDE4D |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 14 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| WO-2010114493-A1 | LANTHANIDE METAL COMPLEXES USEFUL IN TREATING CANCER | AGENCY FOR SCIENCE, TECHNOLOGY AND RESEARCH (SG) | 2010-10-07 | — | — | WO | claimed |
| US-20160369237-A1 | METHODS TO ACCELERATE THE ISOLATION OF NOVEL CELL STRAINS FROM PLURIPOTENT STEM CELLS AND CELLS OBTAINED THEREBY | ADVANCED CELL TECH INC (US) | 2016-12-22 | — | — | US | disclosed |
| US-20120077792-A1 | LANTHANIDE METAL COMPLEXES USEFUL IN TREATING CANCER | NATIONAL UNIVERSITY OF SINGAPORE (SG) | 2012-03-29 | — | — | US | disclosed |
| WO-2010114493-A1 | LANTHANIDE METAL COMPLEXES USEFUL IN TREATING CANCER | AGENCY FOR SCIENCE, TECHNOLOGY AND RESEARCH (SG) | 2010-10-07 | — | — | WO | disclosed |
| US-20100184033-A1 | METHODS TO ACCELERATE THE ISOLATION OF NOVEL CELL STRAINS FROM PLURIPOTENT STEM CELLS AND CELLS OBTAINED THEREBY | Lineage Cell Therapeutics, Inc. | 2010-07-22 | — | — | US | disclosed |
| US-20100162416-A1 | Multi-stage stem cell carcinogenesis | STEMLIFELINE, INC. (US) | 2010-06-24 | — | — | US | disclosed |
| WO-2010037134-A2 | MULTI-STAGE STEM CELL CARCINOGENESIS | STEMLIFELINE, INC. (US) | 2010-04-01 | — | — | WO | disclosed |
| US-20080226601-A1 | Herpes Virus-Based Compositions and Methods of Use in the Prenatal and Perinatal Periods | UNIVERSITY OF ROCHESTER (US) | 2008-09-18 | — | — | US | disclosed |
| EP-1903873-A2 | HERPES VIRUS-BASED COMPOSITIONS AND METHODS OF USE IN THE PRENATAL AND PERINATAL PERIODS | THE UNIVERSITY OF ROCHESTER (US) | 2008-04-02 | — | — | EP | disclosed |
| US-20080070303-A1 | Using myocardial and/or muscle progenitor cells as modeling tool in tissue engineering; regenerative medicine and organ replacement | ADVANCED CELL TECHNOLOGY | 2008-03-20 | — | — | US | disclosed |
| WO-2006135602-A2 | HERPES VIRUS-BASED COMPOSITIONS AND METHODS OF USE IN THE PRENATAL AND PERINATAL PERIODS | UNIVERSITY OF ROCHESTER (US) | 2006-12-21 | — | — | WO | disclosed |
| US-6004966-A | ANTIISCHEMIC AGENTS; PYRAZOLO(3,4-D)PYRIMIDINDE, PURINE, ANDPTERIDINE DERIVATIVES | BTG INTERNATIONAL LIMITED (GB) | 1999-12-21 | — | — | US | disclosed |
| EP-0796099-A1 | USE OF XANTHINE OXIDASE INHIBITORS AS ANTI-ISCHAEMIC AGENTS | BTG INTERNATIONAL LIMITED (GB) | 1997-09-24 | — | — | EP | disclosed |
| WO-1996017610-A1 | USE OF XANTHINE OXIDASE INHIBITORS AS ANTI-ISCHAEMIC AGENTS | BRITISH TECHNOLOGY GROUP LIMITED (GB) | 1996-06-13 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20120077792-A1 | LANTHANIDE METAL COMPLEXES USEFUL IN TREATING CANCER | IAPP, RNASE1, LETM1 | ADORA2A 4738/4885PDE4A 3649/4885PDE4B 3747/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.